ライフサイエンスコーパス: IU

1 highest cutoffs evaluated (15mm TST, >=1.00 IU/mL QFT, >=8 spots TSPOT), TST and QFT specificity was

2 for QFT-GIT >=0.35 IU/ml vs. 3.6% for >=4.00 IU/ml; 3.4% for T-SPOT.TB >=5 spots vs. 5.0% for >=50 sp

3 or QFT-GIT >=0.35 IU/ml vs. 23.2% for >=4.00 IU/ml; 65.4% for T-SPOT.TB >=5 spots vs. 27.2% for >=50

4 ded incidence of hepatotoxicity (ALT > 1,000 IU/L), peak international normalized ratio (INR), and ad

5 five intramuscular PEG-asp injections (1,000 IU/m(2)) every two weeks and were then randomly assigned

6 0 IU (n = 109), 4000 IU (n = 100), or 10 000 IU (n = 102).

7 00 IU group and -4.1 mg HA/cm3 in the 10 000 IU group (95% CI, -6.0 to -2.2), with mean percent chang

8 (400 IU), -1.0% (4000 IU), and -1.7% (10 000 IU).

9 at viral load cutoffs of >=1000 and >=10 000 IU/mL in the CMV IVIG arm.

10 % had post-treatment Week 12 HCV RNA >10 000 IU/mL, above reported sensitivity limits of novel diagno

11 e randomized to receive 600, 4,000 or 10,000 IU/d of vitamin D(3) for 6 months.

12 Vitamin D(3) supplementation at 10,000 IU/d produced genomic alterations several fold higher th

13 of 200 000 IU vitamin D3 followed by 100 000 IU monthly (n = 2558) or placebo (n = 2552) until late 2

14 of 200,000 IU vitamin D3 followed by 100,000 IU monthly (n=2,558) or placebo (n=2,552) until late 201

15 3.3 y, monthly supplementation with 100,000 IU vitamin D3 did not affect the incidence rate of kidne

16 l investigated the impact of monthly 100,000 IU vitamin D3 supplementation over several years on card

17 receive a weekly oral dose of either 14,000 IU of vitamin D(3) or placebo for 3 years.

18 f VEG-ECT with intravenous bleomycin (15,000 IU/m(2)) and concomitant electric pulses applied through

19 reaction, patients were started with 20,000 IU/m(2) Erwinia asparaginase 3 times per week, and l-asp

20 of patients with a high viral load (>=20,000 IU/mL).

21 andomized to an initial oral dose of 200 000 IU vitamin D3 followed by 100 000 IU monthly (n = 2558)

22 ine with current practice, a routine 200,000 IU VA capsule was administered after the RID test.

23 andomized to an initial oral dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly (n=2,558) o

24 doses of placebo or 4,200, 16,800, or 28,000 IU of vitamin D3 throughout pregnancy.

25 In treatment groups (4,200, 16,800, 28,000 IU) vs. placebo, neonatal cord blood lead levels were 8.

26 treatment groups (4,200, 16,800, and 28,000 IU, respectively) vs. placebo; however, 95% confidence i

27 usage decreased by 15,000, 15,000, or 33,000 IU/wk per patient in the 2-, 6-, and 20-mg ziltivekimab

28 c alterations several fold higher than 4,000 IU/d even without further changes in PTH levels.

29 a monthly dose of 12,000, 24,000, or 48,000 IU, respectively (P < 0.01 for difference).

30 IU/ml compared to patients with HBsAg >5,000 IU/ml.

31 ned 1:1 to receive either weekly oral 50 000 IU vitamin D(3) supplements (cholecalciferol) for the fi

32 e pulmonary exacerbation, followed by 50,000 IU of vitamin D3 or an identically matched placebo pill

33 serum HBsAg levels <500 (HBs(lo)) or >50,000 IU/ml (HBs(hi)) using immunological assays (flow cytomet

34 ts received a single enteral dose of 540,000 IU of vitamin D(3) or matched placebo.

35 monthly cholecalciferol (equivalent to 9,000 IU/week), (3) thrice-weekly placebo, or (4) once-monthly

36 p; and 78.4, 188.0, and 144.4 for the 10 000-IU group.

37 :1:1 ratio to either (1) thrice-weekly 3,000-IU cholecalciferol, (2) once-monthly cholecalciferol (eq

38 ere established at 6.02log IU/mL and 4.02log IU/mL, respectively.

39 -/out any HCV+SS were established at 6.02log IU/mL and 4.02log IU/mL, respectively.

40 pegIFN + NAP regimen, HBsAg levels were 0.05 IU/mL or lower in 24/40 participants (all with seroconve

41 ferase) or functional cure (HBsAg below 0.05 IU/mL, HBV DNA target not detected, normal level of alan

42 TR group than in the KTC group (1.85 vs 1.06 IU/mL, P = .046).

43 determination of BLC-specific IgE below 0.1 IU/mL, thus allowing identification of allergic patients

44 h specificity towards beechwood xylan (288.1 IU/mg), with the optimum activity at 50 degrees C and a

45 NAP groups had decreases in HBsAg to below 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P

46 severe hemophilia A (factor VIII level, <=1 IU per deciliter) who had received a single infusion of

47 ol/L medroxyprogesterone acetate (MPA) +/- 1 IU/mL thrombin pretreatment for 4 hours, washed, and the

48 m) had factor VIII expression of less than 1 IU per deciliter, as assessed on chromogenic assay.

49 tive concentration of antibody was set at 10 IU/mL by extrapolation of functional assay correlates; h

50 Hepatitis B surface antibody (anti-HBs) <10 IU/mL in HBV surface antigen-negative patients and negat

51 meeting questioned the appropriateness of 10 IU/mL as the cutoff for protection and acknowledged the

52 S) samples was calculated to be 2.43 log(10) IU/ml (267 IU/ml; 95% CI, 2.31 to 2.73 log(10) IU/ml [20

53 e 13, 52) and median HCV RNA was 6.2 log(10) IU/mL (range 0.9, 7.7).

54 /ml (267 IU/ml; 95% CI, 2.31 to 2.73 log(10) IU/ml [204 to 540 IU/ml]).

55 has a reproducibility of SD <= 0.16 log(10) IU/mL and an accuracy of <= 0.22 log(10) IU/mL differenc

56 10) IU/mL and an accuracy of <= 0.22 log(10) IU/mL difference when compared to the assigned values.

57 DNA declines from baseline were 1.7 log(10) IU/mL in the 100 mg dose cohort, 2.1 log(10) IU/mL in th

58 IU/mL in the 100 mg dose cohort, 2.1 log(10) IU/mL in the 200 mg dose cohort, and 2.8 log(10) IU/mL i

59 L in the 200 mg dose cohort, and 2.8 log(10) IU/mL in the 300 mg dose cohort.

60 st assays yielded results within 0.5 log(10) IU/ml of the mean for CMV, while for EBV a greater varia

61 V a greater variability of up to 1.5 log(10) IU/ml of the mean was shown.

62 Passing-Bablok regression of log(10) IU/ml values revealed a regression line of Y = 1.163 x X

63 Median baseline HBV DNA was 8.2 log(10) IU/mL, and ALT was 0.9 times the ULN.

64 detected with an accuracy of +/- 0.3 log(10) IU/mL.

65 ransaminases level, and if AST are above 100 IU/L, they should be aware of a possible overestimation

66 ginase and Erwinia asparaginase levels > 100 IU/L, respectively.

67 gh levels of nonallergic patients were > 100 IU/L.

68 ts with aspartate aminotransferase (AST)>100 IU/L and 50 IU/L showed significantly higher values of L

69 hange in ASCs among patients with HBsAg <100 IU/ml compared to patients with HBsAg >5,000 IU/ml.

70 s ALT doubling and peak ALT greater than 100 IU/L, indicating the need for further antidotal treatmen

71 defined as either plasma CMV DNAemia >= 1000 IU/mL with/without clinical symptoms or <1000 IU/mL with

72 s defined as either plasma CMV DNAemia>=1000 IU/ml with/without clinical symptoms or <1000 IU/ml with

73 U/mL with/without clinical symptoms or <1000 IU/mL with symptoms.

74 U/ml with/without clinical symptoms or <1000 IU/ml with symptoms.

75 d HIV RNA<400 copies/mL and 83% HBV DNA<1000 IU/mL.

76 stimated to increase from 516.1 million 1000 IU vials (95% CI 409.0 million-658.6 million) per year i

77 itamin D(3) supplementation at doses of 1000 IU/d or higher did not prevent falls compared with 200 I

78 ty concerns about vitamin D(3) doses of 1000 IU/d or higher.

79 mited to the period they were receiving 1000 IU/d; n = 308) and those randomly assigned to receive 20

80 asma HCV RNA concentration of more than 1000 IU/mL at screening.

81 ctal adenoma, were randomly assigned to 1000 IU/d of vitamin D3 or placebo and 1200 mg/d of calcium c

82 centrations of the autoantibodies up to 1000 IU/mL.

83 c-diastolic BP was lower at 6 mo in the 1000-IU group [-2.66 (95% CI: -5.27, -0.046), -3.57 (-5.97, -

84 2000- and 4000-IU/d doses than for the 1000-IU/d dose, which was selected as the best dose (posterio

85 red with patients in the placebo group (1009 IU/L [208 to 1809]; p=0.014).

86 Fol (mean 95% confidence interval [CI]; 0.11 IU/mL, 0.09-0.12), antenatal supplementation with MMN or

87 Supplementation with 1200 IU/d vitamin D for 12 mo had no effect on depressive sym

88 tcomes were CMV events (CMV DNA level >=1250 IU/mL, CMV viremia requiring antiviral treatment, or end

89 Of 128 IU-CRLM patients, 51 (40%) underwent CTR at median 6 mon

90 m) had a median factor VIII expression of 13 IU per deciliter; the median annualized rate of bleeding

91 e groups at the end of treatment for AST 130 IU/L [95% CI 54 to 205; p=0.0009] and for ALT 61 IU/L [2

92 lus rifaximin and placebo group (for AST -14 IU/L [-91 to 64; p=0.728] and for ALT -8 IU/L [-49 to 33

93 had a geometric mean titer of 20 IU/mL vs 14 IU/mL for the 2-dose PEP schedule (P = .0228).

94 results indicate that pH 3, 40 degrees C, 15 IU/ml, and 10 h incubation were the optimal conditions f

95 efficacy endpoint was SVR12 (ie, HCV RNA <15 IU/mL at 12 weeks post-treatment), assessed within each

96 al response, defined as HCV RNA less than 15 IU/mL at 12 weeks after completion of treatment (SVR12),

97 e daily for the first month, followed by 150 IU per kilogram once daily).

98 s vein bleeding 7 days after infusion of 150 IU/kg FIX), FIX(WT) and the increased half-life FIXs Alp

99 variables at month 6: high-level EBVd (>1500 IU/mL) and recurrent infection during the previous month

100 after transplantation, with a median of 1800 IU per milliliter (interquartile range, 800 to 6180).

101 atients with a negative QFN-CMV assay (< 0.2 IU/mL) received prolonged valganciclovir prophylaxis.

102 vastatin 20 mg/day plus rifaximin group (4.2 IU/L [-804 to 813]; p=0.992).

103 nti-pertussis toxin IgG concentration of <20 IU/ml were inoculated intranasally with non-attenuated,

104 m) had a median factor VIII expression of 20 IU per deciliter; the median number of annualized treate

105 EP schedule had a geometric mean titer of 20 IU/mL vs 14 IU/mL for the 2-dose PEP schedule (P = .0228

106 istered MDMA (0.75, 1.5 mg/kg), oxytocin (20 IU), and placebo in randomized, double-blind fashion.

107 ed a decrease of the viral load (VL) to <200 IU/mL after letermovir therapy.

108 or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily for the first

109 ) and those randomly assigned to receive 200 IU/d (n = 339) (hazard ratio [HR], 0.94 [95% CI, 0.76 to

110 ollees were randomly assigned to receive 200 IU/d or the best dose.

111 decrease of the viral load to less than 200 IU/mL after letermovir therapy.

112 inear calibration plot ranging from 1 to 200 IU mL(-1) with a LOD of 0.3 IU mL(-1) for anti-dsDNA AAb

113 gher did not prevent falls compared with 200 IU/d.

114 perience-with-best-dose group versus the 200-IU/d group (serious fall: HR, 1.87 [CI, 1.03 to 3.41]; f

115 s were randomized to receive either: 1) 2000 IU vitamin D-3 (Vit D) per day; 2) 4000 mg CLA per day;

116 arine n-3 FAs (1 g/d) and vitamin D(3) (2000 IU/d) in the primary prevention of CVD and cancer among

117 control (HBsAg positive, HBV DNA below 2000 IU/mL, normal level of alanine aminotransferase) or func

118 tional counseling; and daily vitamin D (2000 IU), calcium (600 mg), and multivitamins.

119 2) 4000 mg CLA per day; 3) both Vit D (2000 IU/d) and CLA (4000 mg/d); or 4) placebo for 8 wk.

120 a 2 x 2 factorial design to vitamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 w

121 were randomized to receive vitamin D3 (2000 IU/d) and omega-3 fatty acids (eicosapentaenoic acid and

122 While daily 2000 IU and 800 IU vitamin D3 reduced mean systolic BP over 2

123 he first month of ART followed by daily 2000 IU vitamin D(3) supplements or a matching weekly and dai

124 randomly assigned to receive high dose (2000 IU) or standard dose (800 IU) daily vitamin D3 for 24 mo

125 over 2 y to a small and similar extent, 2000 IU reduced mean systolic BP variability significantly mo

126 vention in 1 of the following 8 groups: 2000 IU/d of vitamin D3, 1 g/d of omega-3s, and a strength-tr

127 ng patients had an episode of HBV DNA >=2000 IU/mL in a mean follow-up of 68.8 months.

128 Pretreatment HBV DNA >=2000 IU/mL is associated with increased risk of liver-related

129 vestigation outcomes included HBV DNA >=2000 IU/mL, with or without alanine aminotransferase (ALT) >=

130 her pretreatment viral load (>=2000 vs <2000 IU/mL) was associated with increased risks of clinical r

131 patients with pretreatment viral load <2000 IU/mL, clinical relapse occurred in 10 (19.6 %) and hepa

132 min D(3) (cholecalciferol) at a dose of 2000 IU per day and marine n-3 (also called omega-3) fatty ac

133 l design, of vitamin D(3) (at a dose of 2000 IU per day) and marine n-3 fatty acids (at a dose of 1 g

134 ffer between children receiving 1000 or 2000 IU vitamin D and children receiving 600 IU.

135 supplementation with vitamin D3 1000 or 2000 IU/d is more effective than 600 IU/d in improving arteri

136 vitamin D3 supplementation with 1000 or 2000 IU/d versus 600 IU/d did not affect measures of arterial

137 adults randomly assigned to placebo or 2000 IU/d.

138 pants were randomly assigned to receive 2000 IU vitamin D3, 1000 mg fish oil, or placebo daily for 6

139 oth HBV DNA concentrations of less than 2000 IU/mL and ALT concentrations less than the ULN at TFFU w

140 had HBsAg loss or HBV DNA of less than 2000 IU/mL and one (14%) had an ALT less than the ULN at week

141 mean systolic BP reduction between the 2000 IU (n = 123) and 800 IU (n = 127) groups was not statist

142 the placebo group and 6.8 ng/mL in the 2000 IU/d group (absolute difference: 6.9; 95% CI: 4.5, 9.3 n

143 serum vitamin D3 was 10.4 ng/mL in the 2000 IU/d group and 22.2 ng/mL in the 4000 IU/d group (fold d

144 We tested whether 2000 IU is superior to 800 IU vitamin D3/d for cognitive perf

145 iability was significantly reduced with 2000 IU (average real variability: -0.37 mm Hg) compared to 8

146 if daily vitamin D supplementation with 2000 IU is more effective than 800 IU for BP control among ol

147 .67; 95% CI: -4.88, -0.46 mg/dL) in the 2000-IU group.

148 [ALT, weighted mean difference (WMD): -11.23 IU/L; 95% CI: -15.02, -7.44 IU/L] and liver stiffness me

149 ndomly administered a single dose of OXT (24 IU), LZP (1 mg), or placebo.

150 of at least 75 ng per milliliter (or >=0.25 IU per milliliter for those receiving enoxaparin).

151 at the same corresponding dose of either 25 IU or 65 IU per kilogram.

152 n of recombinant factor VIII at a dose of 25 IU per kilogram of body weight (lower-dose group) or 65

153 ric mean titer of 37 IU/mL, compared with 25 IU/mL for the single-dose 3-visit schedule (P < .001).

154 iosensor showed a limit of detection of 0.26 IU/mL (624 pg/mL) and 14 ng/mL for IgE and IgG antibodie

155 was calculated to be 2.43 log(10) IU/ml (267 IU/ml; 95% CI, 2.31 to 2.73 log(10) IU/ml [204 to 540 IU

156 ng from 1 to 200 IU mL(-1) with a LOD of 0.3 IU mL(-1) for anti-dsDNA AAbs standards.

157 ansferase: - 27.2, - 7.2, - 39.2, and - 16.3 IU/L, respectively; all p < 0.010).

158 on and clearance of ~10(8) [10(7.7)-10(8.3)] IU/day.

159 A pretreatment HBV DNA level of 300 IU/mL predicts HBV flare and HBsAg seroclearance after a

160 or very low viral load (VLVL; HCV RNA <=3000 IU/mL).

161 duals were randomly assigned to receive 3000 IU (75 ug) vitamin D3 or placebo daily for 26 wk.

162 cohort, patients with levels of at least 34 IU/mL had a significantly lower 90-day survival (59%) co

163 red with those with ASCA levels less than 34 IU/mL (80%) with an adjusted hazard ratio of 3.13 (95% C

164 ing standard U.S. cutoffs (>=5mm TST, >=0.35 IU/mL QFT, >=8 spots TSPOT).

165 aned for all tests (61.0% for QFT-GIT >=0.35 IU/ml vs. 23.2% for >=4.00 IU/ml; 65.4% for T-SPOT.TB >=

166 e higher thresholds (3.0% for QFT-GIT >=0.35 IU/ml vs. 3.6% for >=4.00 IU/ml; 3.4% for T-SPOT.TB >=5

167 defined as at least one positive IgE (>=0.35 IU/mL) to common aeroallergens, and asthma was defined a

168 ID schedule had a geometric mean titer of 37 IU/mL, compared with 25 IU/mL for the single-dose 3-visi

169 combination, resulting in a potency of 79.4 IU/mg in the in vivo intradermal challenge assay.

170 men with alanine aminotransferase (ALT) >=40 IU/L as a predictor of high HBV DNA level.

171 47 (9.1%) were HBeAg negative with ALT >=40 IU/L, and 144 (28.0%) had an HBV DNA >5.3 log10 IU/mL.

172 resonance imaging study, a single dose of 40 IU of oxytocin was administered via nasal spray to male

173 ith mean percent change values of -0.4% (400 IU), -1.0% (4000 IU), and -1.7% (10 000 IU).

174 Daily doses of vitamin D3 for 3 years at 400 IU (n = 109), 4000 IU (n = 100), or 10 000 IU (n = 102).

175 igurations were compared for delivery of 400 IU/mL insulin solution by measuring droplet size distrib

176 d those born to mothers who had received 400 IU of vitamin D(3) per day (control group).

177 bial volumetric BMD differences from the 400 IU group were -1.8 mg HA/cm3 (95% CI, -3.7 to 0.1) in th

178 were 76.3, 76.7, and 77.4 nmol/L for the 400-IU group; 81.3, 115.3, and 132.2 for the 4000-IU group;

179 change values of -0.4% (400 IU), -1.0% (4000 IU), and -1.7% (10 000 IU).

180 min D3 for 3 years at 400 IU (n = 109), 4000 IU (n = 100), or 10 000 IU (n = 102).

181 icipants were randomized to vitamin D3, 4000 IU/d (n = 96), or placebo (n = 96) for 48 weeks and main

182 ere randomly assigned to receive either 4000 IU vitamin D3 or placebo daily for 24 wk.

183 ts report vitamin D intakes of at least 4000 IU per day.

184 tamin D(3) supplementation at a dose of 4000 IU per day did not result in a significantly lower risk

185 200 (control), 1000, 2000, or 4000 IU of vitamin D(3) per day.

186 15 adults randomly assigned to 2000 or 4000 IU/d.

187 nostic criteria for diabetes to receive 4000 IU per day of vitamin D(3) or placebo, regardless of the

188 mg HA/cm3 (95% CI, -3.7 to 0.1) in the 4000 IU group and -4.1 mg HA/cm3 in the 10 000 IU group (95%

189 e 2000 IU/d group and 22.2 ng/mL in the 4000 IU/d group (fold difference: 2.15; 95% CI: 1.40, 3.37).

190 ome rates were higher for the 2000- and 4000-IU/d doses than for the 1000-IU/d dose, which was select

191 U group; 81.3, 115.3, and 132.2 for the 4000-IU group; and 78.4, 188.0, and 144.4 for the 10 000-IU g

192 LOD) of 10.65 IU/mL in EDTA-plasma and 12.43 IU/mL in serum.

193 ce (WMD): -11.23 IU/L; 95% CI: -15.02, -7.44 IU/L] and liver stiffness measurement (LSM) by elastogra

194 ildren born to mothers who had received 4400 IU of vitamin D(3) per day during pregnancy (vitamin D g

195 dian PEGasparaginase dose was lowered to 450 IU/m(2).

196 showed an estimated relative potency of 454 IU/mg and minimal effective dose 50% (MED50%) of 3.0 pM

197 rgic asthmatic subjects (total IgE, 133-4692 IU/mL; n = 28) and healthy nonallergic controls (n = 12)

198 PE + MMN group than in the FeFol group (3.47 IU/mL, 3.29-3.66).

199 ia and is optimal at a mid-range dose (36-48 IU).

200 significantly enhanced at doses of 36 and 48 IU in comparison to placebo, but not at other doses.

201 d intranasal administrations of oxytocin (48 IU/day) in adult males with autism spectrum disorder.

202 ctable CMV DNA (median plasma viral load 498 IU/mL, interquartile range [IQR] 259-2390).

203 ubjects with an adequate antibody level >0.5 IU/mL 7 days after the booster injection.

204 cepted neutralizing antibody titers of >=0.5 IU/mL following the second rabies vaccination dose and m

205 virus neutralizing antibodies titers >= 0.5 IU/mL on day 14.

206 roups possessed a rabies antibody titer >0.5 IU/mL on day 7 following the booster dose.

207 e seropositive (antibody concentration >=0.5 IU/mL) 4.5 years after vaccination.

208 ipants with an adequate antibody level (>0.5 IU/mL) 7 days after the booster doses.

209 WHO-2 SRIGs, were: 1.8 IU/mL (18.7%) and 1.5 IU/mL (17.8%) for IMORAB2; and 2.9 IU/mL (17.5%) and 2.5

210 e impairments were mimicked by insulin (11.5 IU/kg) and mitigated by glucose, demonstrating that acut

211 ) for IMORAB2; and 2.9 IU/mL (17.5%) and 2.5 IU/mL (16.7%), respectively, for GCIRAB1.

212 increased AUC of LH exposure (169.0 vs. 38.5 IU.h/L; P = 0.0058).

213 rtate aminotransferase (AST)>100 IU/L and 50 IU/L showed significantly higher values of LS if compare

214 RNA by polymerase chain reaction assay (<50 IU/mL) 12 weeks after the end of treatment (SVR) or an u

215 minase and alanine transaminase less than 50 IU/mL.

216 ter r-aP + Td (113.74 [95% CI, 88.31-146.50] IU/mL; P = .0006).

217 w after cd/Tdap (52.43 [95% CI, 36.41-75.50] IU/mL) and 2-fold higher after r-aP + Td (113.74 [95% CI

218 [95% confidence interval {CI}, 49.88-109.52] IU/mL) and approximately 2-fold higher after r-aP + Td (

219 ter r-aP + Td (127.68 [95% CI, 96.73-168.53] IU/mL; P = .0162).

220 % CI, 2.31 to 2.73 log(10) IU/ml [204 to 540 IU/ml]).

221 respectively, than in the FeFol group (0.55 IU/mL, 0.52-0.58).

222 ed that BPF99 reduced ALT (mean 71.6 vs 44.6 IU/l, p < 0.01), triglycerides (38.8 vs 28.1 mg/dl, p <

223 ts of detection in serum are 1.7 IU/mL and 6 IU/mL for anti-TPO and anti-TG, respectively.

224 IL-2 alone (0.3 x 10(6) IU/m(2) or 1 x 10(6) IU/m(2)) or rapamycin alone (0.5-1

225 IL-2 alone (0.3 x 10(6) IU/m(2) or 1 x 10(6) IU/m(2)) or rapamycin alone (0.5-1 mg/kg) for 3 weeks di

226 in E (DE), 465 mg DHA plus placebo (DP), 600 IU vitamin E plus placebo (EP), or both placebo capsules

227 Participants took daily 465 mg DHA plus 600 IU vitamin E (DE), 465 mg DHA plus placebo (DP), 600 IU

228 2000 IU vitamin D and children receiving 600 IU.

229 1000 or 2000 IU/d is more effective than 600 IU/d in improving arterial endothelial function, arteria

230 ementation with 1000 or 2000 IU/d versus 600 IU/d did not affect measures of arterial endothelial fun

231 Compared with the 600-IU group, central-systolic, central-diastolic, and syste

232 T-6-free IGRA cutoff was established at 0.61 IU/mL, based on receiver operating characteristic analys

233 [95% CI 54 to 205; p=0.0009] and for ALT 61 IU/L [22 to 100; p=0.0025].

234 mL, with a limit of detection (LOD) of 10.65 IU/mL in EDTA-plasma and 12.43 IU/mL in serum.

235 gram of body weight (lower-dose group) or 65 IU per kilogram (higher-dose group).

236 ame corresponding dose of either 25 IU or 65 IU per kilogram.

237 tivity: limits of detection in serum are 1.7 IU/mL and 6 IU/mL for anti-TPO and anti-TG, respectively

238 (HBeAg)-positive adults with HBV DNA > 10(7) IU/mL and alanine aminotransferase (ALT) <= 1.5 times th

239 s a linear quantitative range of 15 to 10(7) IU/mL, with a limit of detection (LOD) of 10.65 IU/mL in

240 ent atopy by blood specific IgE level > 0.70 IU/mL to 1 or more of 10 common allergens.

241 otransferase (61.13 + 24.77 vs 73.17 + 53.71 IU/L; P = 0.04), and prothrombin time-international norm

242 RA patients displaying RF-IgA levels >75 IU/mL exhibited five-fold more abundant P. gingivalis le

243 the low-dose group (median difference, -7539 IU; 95% confidence interval [CI], -9485 to -5582).

244 erythropoiesis-stimulating agent was 29,757 IU in the high-dose group and 38,805 IU in the low-dose

245 ted against WHO-1 and WHO-2 SRIGs, were: 1.8 IU/mL (18.7%) and 1.5 IU/mL (17.8%) for IMORAB2; and 2.9

246 -14 IU/L [-91 to 64; p=0.728] and for ALT -8 IU/L [-49 to 33; p=0.698]).

247 ly improved the yield of WNV-DeltaNS1 (10(8) IU/ml).

248 uction between the 2000 IU (n = 123) and 800 IU (n = 127) groups was not statistically significant (-

249 While daily 2000 IU and 800 IU vitamin D3 reduced mean systolic BP over 2 y to a sma

250 ve high dose (2000 IU) or standard dose (800 IU) daily vitamin D3 for 24 mo.

251 35, 0.94); no association was found for >800 IU/d.

252 inverse associations between intake of <=800 IU/d (compared with nonuse) and risk of several subtypes

253 tion with 2000 IU is more effective than 800 IU for BP control among older adults.

254 al variability: -0.37 mm Hg) compared to 800 IU vitamin D3 (0.11 mm Hg; difference: -0.48 mm Hg; 95%

255 We tested whether 2000 IU is superior to 800 IU vitamin D3/d for cognitive performance among relative

256 ability significantly more compared with 800 IU.

257 29,757 IU in the high-dose group and 38,805 IU in the low-dose group (median difference, -7539 IU; 9

258 oses of OT (8, 12, 24, 36, 48, 60, 72, or 84 IU).

259 itres in the PP on day 14 were 4.38 and 4.85 IU/mL, for the TwinrabTM and HRIG arms, respectively.

260 L; P = 0.0008) and total IgE (-7.90 vs -1.86 IU/mL; P = 0.022).

261 s 28 days after vaccination: 2.3 versus 6.87 IU/mL, respectively (P < .001, t test).

262 ) and 1.5 IU/mL (17.8%) for IMORAB2; and 2.9 IU/mL (17.5%) and 2.5 IU/mL (16.7%), respectively, for G

263 p < 0.001 (95% CI 0.72 to 1.09), gammaGT 7.9 IU/l (95% CI 4.14 to 11.65) and homocysteine 4.6 mumol/l

264 groups, compared with the FeFol group (74.9 IU/mL, 67.8-82.8).

265 ents with HBV DNA levels from 2000 to 19,999 IU/mL (intermediate viral load [IVL]) and normal levels

266 Specimens from IU-CRLM patients receiving systemic/HAI chemotherapy (20

267 Genomic correlates of CTR and OS in IU-CRLM have not been previously explored.

268 n international units (IU); the reporting in IU for assays calibrated with an IS (or secondary standa

269 /out any HCV+SS were established at 6.02 log IU/mL and 4.02 log IU/mL, respectively.

270 e established at 6.02 log IU/mL and 4.02 log IU/mL, respectively.

271 irus (CMV) viral loads overall were 0.29 log IU/mL higher with cobas CMV for use on the cobas 6800/88

272 .28 [IQR, 0.85] log IU/mL vs 4.08 [2.45] log IU/mL; P < .001).

273 Median HBV DNA was 7.77 log IU/mL (range, 4.11-10.06), and 49 (20.4%) were HBeAg-pos

274 s with HCV-negative SS (6.28 [IQR, 0.85] log IU/mL vs 4.08 [2.45] log IU/mL; P < .001).

275 = 6.7 log10 IU/mL and changed by -4.1 log10 IU/mL by Day 7.

276 median baseline HCV RNA load was 6.17 log10 IU/mL (interquartile range 4.51 - 6.55).

277 were 61.8% and 99.2% for HBV DNA >5.3 log10 IU/mL and 81.3% and 96.7% for HBV DNA >7.3 log10 IU/mL.

278 79.2% and 93.3% for HBV DNA level >5.3 log10 IU/mL and 92.7% and 88.1% for HBV DNA >7.3 log10 IU/mL.

279 ify HBV DNA >2 thresholds (5.3 and 7.3 log10 IU/mL) were evaluated.

280 L, and 144 (28.0%) had an HBV DNA >5.3 log10 IU/mL.

281 L and 81.3% and 96.7% for HBV DNA >7.3 log10 IU/mL.

282 L and 92.7% and 88.1% for HBV DNA >7.3 log10 IU/mL.

283 iral loads ranging between 2.9 and 6.6 log10 IU/mL.

284 lasma HCV ribonucleic acid (RNA) = 6.7 log10 IU/mL and changed by -4.1 log10 IU/mL by Day 7.

285 32% HBeAg-positive, median HBV DNA 4.8 log10 IU/ml (undetectable-8.4), median FibroScan 5.3kPa (3.0-6

286 in larger datasets, may impact treatment of IU-CRLM patients.

287 sely associated with BMI (-0.018 kg/m(2) per IU/L, 95% CI -0.024 to -0.012).

288 tively associated with BMI (0.10 kg/m(2) per IU/L, 95% confidence interval (CI) 0.09 to 0.11).

289 and a real data application, we compare the IU test with commonly used variance component tests.

290 ese challenges, we develop an integrative U (IU) method for the design and analysis of multi-level om

291 Unitage (IU/mL) was assigned using WHO-1 and WHO-2 SRIGs as calib

292 single dose of 250,000 International Units (IU) or to placebo within 72 h of hospital admission for

293 xpected to use insulin, international units (IU) required, and DALYs averted per year under alternati

294 itation ranged from 442 international units (IU)/ml (EBV) to 661 copies/ml (VZV).

295 s of ISs are defined in international units (IU); the reporting in IU for assays calibrated with an I

296 agate at low levels (10(5) infectious units [IU]/ml) in a 293T cell line expressing wild-type (WT) NS

297 iated with CTR and survival in patients with IU-CRLM treated with HAI/systemic chemotherapy.

298 In patients presenting with IU-CRLM, combination systemic and HAI chemotherapy enabl

299 dose group and 12,800 hours vs. 1960 hours x IU per deciliter in the higher-dose group).

300 two dose groups (4470 hours vs. 638 hours x IU per deciliter in the lower-dose group and 12,800 hour